Investor Nextech V Oncology S.C.S., SICAV-SIF
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Nextech V Oncology S.C.S., SICAV-SIF . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-02-14 13G/A KNTE / Kinnate Biopharma Inc. 2,329,480 0
2023-02-14 13G/A KNTE / Kinnate Biopharma Inc. 3,008,243 2,329,480
2022-02-14 13G/A PMVP / PMV Pharmaceuticals, Inc. 2,528,290 1,385,807
2021-02-16 13G KNTE / Kinnate Biopharma Inc. 3,008,243
2021-02-16 13G PMVP / PMV Pharmaceuticals, Inc. 2,528,290
2021-02-16 13G/A IDYA / IDEAYA Biosciences, Inc. 1,403,823 0
2020-02-13 13G/A ARVN / Arvinas, Inc. 1,694,351
2020-02-13 13G IDYA / IDEAYA Biosciences, Inc. 1,403,823
2019-02-13 13G ARVN / Arvinas, Inc. 1,694,351